SPX3,585.62-54.85 -1.51%
DIA287.30-4.91 -1.68%
IXIC10,575.62-161.89 -1.51%

Morgan Stanley Maintains Equal-Weight on Akero Therapeutics, Raises Price Target to $30

Morgan Stanley analyst Matthew Harrison maintains Akero Therapeutics (NASDAQ:AKRO) with a Equal-Weight and raises the price target from $26 to $30.

Benzinga · 09/14/2022 07:31
Morgan Stanley analyst Matthew Harrison maintains Akero Therapeutics (NASDAQ:AKRO) with a Equal-Weight and raises the price target from $26 to $30.